International Flavors & Fragrances Inc. (IFF) reported adjusted earnings of 97 cents per share in fourth-quarter 2024, beating the Zacks Consensus Estimate of 78 cents. The bottom line improved 35% from the year-ago quarter.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Including one-time items, the company reported a loss of 18 cents per share compared with the prior-year quarter’s loss of $10.21.International Flavors’ net sales were $2.77 billion in the December-end quarter, up 2.5 ...

CAUTIONARY STATEMENT Fourth Quarter & Full Year 2024 Earnings Conference Call February 19, 2025 Statements in this presentation release, which are not historical facts or information, are "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on management's current assumptions, estimates and expectations including those concerning expected cash flow and availability of capital resources to fund our operations and me ...

International Flavors (IFF) reported $2.77 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 2.5%. EPS of $0.97 for the same period compares to $0.72 a year ago.The reported revenue represents a surprise of +3.94% over the Zacks Consensus Estimate of $2.67 billion. With the consensus EPS estimate being $0.78, the EPS surprise was +24.36%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to ...

International Flavors (IFF) came out with quarterly earnings of $0.97 per share, beating the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.72 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 24.36%. A quarter ago, it was expected that this ingredients producer for food, cosmetics and consumer products industries would post earnings of $1.06 per share when it actually produced earnings of $1.04, de ...

Financial Performance - Reported net sales for the full year 2024 were $11.48 billion, flat compared to the prior year, with currency neutral sales increasing by 6%[5] - Adjusted operating EBITDA for the full year was $2.21 billion, reflecting a 16% increase on a comparable basis due to strong volume growth and productivity gains[5] - Reported earnings per share (EPS) for the full year was $0.95, while adjusted EPS excluding amortization was $4.31 per diluted share[5] - For the fourth quarter, reported net sales were $2.77 billion, a 3% increase year-over-year, with currency neutral sales up 6%[8] - Adjusted operating EBITDA for the fourth quarter was $471 million, with a comparable increase of 5% driven by volume growth and productivity gains[10] - Net income for the year ended December 31, 2024, was $247 million, a significant improvement from a net loss of $2,563 million in 2023[42] - Reported (GAAP) Net Income for 2024 was $278 million, a recovery from a net loss of $2,518 million in 2023[68] - Adjusted (Non-GAAP) Net Income for the year ended December 31, 2024, was $646 million, up from $328 million in 2023, representing a growth of 96.34%[70] Segment Performance - The Nourish segment reported a 4% increase in comparable currency neutral sales, while Health & Biosciences and Scent segments saw increases of 6% and 7% respectively[9] - The Nourish segment reported net sales of $5,871 million in 2024, down from $6,060 million in 2023, a decrease of about 3.1%[45] - Health & Biosciences segment sales increased by 6.3% to $2,212 million in 2024, compared to $2,081 million in 2023[84] - Scent segment sales grew to $2,440 million in 2024, up 7.1% from $2,277 million in 2023[84] - Pharma Solutions segment sales reached $961 million in 2024, a slight increase from $945 million in 2023[84] - The company experienced a 12% increase in Pharma Solutions sales, with a remarkable 81% increase in segment adjusted operating EBITDA for Q4 2024[89] Future Projections - Full year 2025 sales are expected to be in the range of $10.6 billion to $10.9 billion, with adjusted operating EBITDA projected between $2 billion and $2.15 billion[12] - The company anticipates comparable currency neutral sales growth of 1% to 4% in 2025, with adjusted operating EBITDA expected to grow 5% to 10% year-over-year[13] - Foreign exchange is expected to have a 4% adverse impact on sales growth and a 6% adverse impact on adjusted operating EBITDA growth in 2025[14] - The Pharma Solutions segment is expected to contribute six months of results in 2025 following its divestiture, which is assumed to close on June 30, 2025[12] Expenses and Cash Flow - Research and development expenses increased by 8% to $170 million in Q4 2024 from $157 million in Q4 2023[38] - Selling and administrative expenses rose by 16% to $517 million in Q4 2024, up from $444 million in Q4 2023[38] - Total net cash provided by operating activities decreased to $1,070 million in 2024 from $1,439 million in 2023, reflecting a decline of approximately 25.6%[42] - The company incurred approximately $1,995 million in Selling and Administrative Expenses for 2024, compared to $1,787 million in 2023, reflecting an increase of 11.65%[65] - Net cash used in financing activities was $1,606 million in 2024, a decrease from $1,851 million in 2023, reflecting a reduction of approximately 13.2%[42] Balance Sheet - Total current assets increased to $7,993 million in 2024 from $6,293 million in 2023[40] - Total liabilities decreased to $14,256 million in 2024 from $15,578 million in 2023[40] - The company’s total assets were $28,667 million in 2024, down from $30,978 million in 2023[40] - Total debt as of December 31, 2024, was $9,005 million, resulting in net debt of $8,534 million after accounting for $471 million in cash and cash equivalents[80] Other Notable Items - The company reported a net loss of $46 million in Q4 2024, a significant improvement from a net loss of $2,609 million in Q4 2023[38] - The company recognized a settlement loss of $130 million related to the termination of the pension plan in 2024[74] - The company incurred an impairment of goodwill of $64 million in 2024, a significant reduction from $2,623 million in 2023[45] - Business divestiture costs for Q4 2024 were approximately $56 million, compared to $38 million in Q4 2023, marking an increase of 47.37%[60] - For the year ended December 31, 2024, business divestiture and integration costs were approximately $220 million and $5 million, respectively, compared to $108 million and $59 million in 2023[73]

Wall Street analysts expect International Flavors (IFF) to post quarterly earnings of $0.78 per share in its upcoming report, which indicates a year-over-year increase of 8.3%. Revenues are expected to be $2.67 billion, down 1.4% from the year-ago quarter.The consensus EPS estimate for the quarter has been revised 2.5% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Before a compan ...

International Flavors & Fragrances Inc. (IFF) is scheduled to report fourth-quarter 2024 results on Feb. 18, after the closing bell.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.The Zacks Consensus Estimate for IFF’s revenues is pegged at $2.67 billion, indicating a 1.37% dip from the year-ago reported figure.The consensus estimate for earnings is pegged at 78 cents per share. The consensus estimate for IFF’s earnings has moved down 2.5% in the past 60 days. The estimate indicates ...

International Flavors & Fragrances Inc. (IFF) is poised to gain from the end-market demand for flavors and fragrances. IFF’s initiatives are also expected to aid its performance. Improved volumes across all its segments in recent quarters will also drive the company’s performance.Let us delve deeper and analyze the factors that make International Flavors stock worth holding on to at present.Demand for Flavors & Fragrances Drives IFF’s GrowthInternational Flavors is well-poised to benefit from the demand for ...

Roquette Successfully Completes Inaugural EUR 1.2 billion Bond Offering to Support its Transformative Acquisition of IFF Pharma Solutions Lille, 26th November 2024 – Roquette, a global leader in plant-based ingredients and pharmaceutical excipients for the health and nutrition sectors, successfully completed its inaugural bond offering with a dual tranche for a total of EUR 1.2bn. Both tranches are admitted to trading on Euronext Paris. The bond offering was met with enthusiastic response from high-quality ...

Have you looked into how International Flavors (IFF) performed internationally during the quarter ending September 2024? Considering the widespread global presence of this ingredients producer for food, cosmetics and consumer products industries, examining the trends in international revenues is essential for assessing its financial resilience and prospects for growth.The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its ...